Corrie Detweiler, a professor of molecular, cellular and developmental biology, eyes some samples in the lab. (Photo: CU Boulder)
As scientists around the globe wage war against a novel, deadly virus, one CU Boulder lab is working on new weapons to battle a different microbial threat: a rising tide of antibiotic-resistant bacteria which, if left unchecked, could kill an estimated 10 million people annually by 2050.
“The COVID-19 situation is definitely putting us at risk for increasing resistance to antibiotics, so it’s more important now than ever that we come up with alternative treatments,” said Corrie Detweiler, a professor of molecular, cellular and developmental biology who has spent her career seeking those alternatives.
In a paper published Dec. 18 in the journal PLOS Pathogens, Detweiler and her research team unveil their latest discovery—a chemical compound that works with a host’s innate immune response to push past cellular barriers that help bacteria resist antibiotics.
Along with their other recently published discoveries, the authors say, the finding could lead to a new arsenal for fighting what could be the next big public health threat.
“If we don’t solve the problem of finding new antibiotics or somehow making old antibiotics work again, we are going to see sharply increasing deaths from bacterial infections we thought we had beaten decades ago,” said Detweiler. “This study offers a totally new approach and could point the way toward new drugs that work better and have fewer side effects.”
In the United States alone, 35,000 people die annually from bacterial infections that could not be treated because they’ve grown resistant to existing drugs. Countless others suffer life-threatening bouts with once-easily treatable illnesses like strep throat, urinary tract infections and pneumonia. By 2050, the authors note, there could be more deaths from antibiotic resistance than from cancer.
“As our existing antibiotics adapt and work less, we risk essentially going back to a period 100 years ago, when even a minor infection could mean death,” said Detweiler.
The pandemic has shone even more light on the problem, she notes, as many patients die not from the virus itself but from hard-to-treat secondary bacterial infections.
Meanwhile, she and other scholars worry that heightened use of antibiotics to prevent or treat those secondary infections, while at times necessary, may be exacerbating resistance.
“Fragile healthcare systems in many parts of the world may not withstand the COVID-19 pandemic if also faced with a substantial increase in antimicrobial resistance,” wrote the authors of an editorial in the British Medical Journal in November.
A new arsenal for an evolving war
Most antibiotics in use today were developed in the 1950s, and pharmaceutical companies have since scaled back on research in the field in favor of more profitable ventures.
To feed the pipeline, Detweiler’s lab developed a technique called SAFIRE for screening for new small molecules, which work differently than older drugs.
Of 14,400 candidates screened from a library of existing chemicals, SAFIRE identified 70 that hold promise.
The new paper centers around “JD1,” which appears to be particularly effective at infiltrating what are known as “Gram-negative bacteria.”
With a tough exterior membrane that prevents antibiotics from accessing the cell, and another interior membrane providing a buffer, these bacteria (including Salmonella and E. coli) are inherently difficult to treat.
But unlike other drugs, JD1 takes advantage of the host’s initial immune assault on that outer bacterial membrane, then slips inside and goes after the inner membrane too.
“This is the first study to show that you can target a Gram-negative bacteria’s inner membrane by exploiting the innate immune response of the host,” Detweiler said.
In laboratory and rodent experiments, JD1 reduced the survival and spread of Gram-negative bacteria called Salmonella enterica by 95%.
But while it damaged the bacterial cell membranes, it couldn’t penetrate the fine layer of cholesterol that lined its mammalian host’s cell membranes.
“Bacteria are vulnerable to JD1 in a way that our cells are not,” said Detweiler, noting that for this reason, side-effects would likely be minimal.
Further studies are underway to explore JD1 and other compounds like it.
Meanwhile, Detweiler has formed a spin-off company to help commercialize other compounds that work by inhibiting pumps, called “efflux pumps,” that bacteria use to pump out antibiotics.
“The reality is, evolution is way smarter than all of the scientists put together and these bacteria will continue to evolve to resist what we throw at them,” she said. “We cannot rest on our laurels. We have to keep feeding the pipeline.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Threat of superbugs
- Gender-neutral lavatories ‘have more germs than single-sex ones’
Scientists said findings might reflect heavier overall use on top of different attitudes to cleanliness between men and women ...
- Could Our Deep Cleaning Habits Be Contributing To Superbugs?
Superbugs are strains of bacteria which are resistant to common antibiotics and they are responsible for about 5,000 deaths each year.
- Climate change risks fuelling antibiotic-resistant ‘superbugs’
Simply sign up to the Climate change myFT Digest -- delivered directly to your inbox. Antibiotic-resistant “superbugs” are among the greatest public health threats of our age — and researchers fear ...
- Cats And Dogs Can Spread Antibiotic Resistant Superbugs To Owners
Transfer of bacteria between sick pets and their humans may be contributing to antibiotic resistance, according to new research.
- 'Just in case' antibiotics widely overused during COVID-19, says UN health agency
Antibiotics saw 'extensive overuse' globally among hospitalised COVID-19 patients during the pandemic without improving clinical outcomes, while also potentially increasing the already serious and ...
Go deeper with Google Headlines on:
Threat of superbugs
[google_news title=”” keyword=”threat of superbugs” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Antibiotic-resistant bacteria
- Raw Meat for Pets: Possible Link to Antibiotic-resistant Bacteria
Study shows raw meat fed to animals causes antibiotic resistance to critical antibiotics, which can also be acquired by pet owners when feeding companion animals.
- Antibiotic Alternative Produced by Gram-Positive Bacteria
Due to increasing antibiotic resistance in pathogens causing infections, the development of new antibacterial substances is needed. Scientists are testing out a new group of substances produced by ...
- Pathogens including multi-drug resistant superbugs found on floors, ceilings and door handles of UK hospital toilets
Pathogenic bacteria and fungi, including multi-drug resistant "superbugs" have been found on the floors, ceilings, door handles and other surfaces of hospital toilets in the UK, with patient toilets ...
- A New Class of Antimicrobial Compounds Discovered in Soil Bacteria
Hundreds of thousands of people die every year from antibiotic-resistant infections or from the complications of those infections, and the problem is only | Microbiology ...
- Study finds resistance to critically important antibiotics in uncooked meat sold for human and animal consumption
New research presented at the ESCMID Global Congress (formerly ECCMID) in Barcelona, Spain (27–30 April) has found substantial levels of resistance to critically-important antibiotics in meat sold for ...
Go deeper with Google Headlines on:
Antibiotic-resistant bacteria
[google_news title=”” keyword=”antibiotic-resistant bacteria” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]